🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Today Liquidia announced the company will present three posters at the American Thoracic Society (ATS; American Thoracic Society (ATS)) 2025 International Conference, taking place May 18-21, 2025, in San Francisco. For more information, read today’s press release at bit.ly/3XuUPMb.

The FDA has accepted Liquidia Corporation's (NASDAQ: LQDA) NDA resubmission for YUTREPIA™ (treprostinil) inhalation powder to treat #PAH and #PHILD with a PDUFA goal date of May 24, 2025. See today's press release here: bit.ly/4l3mkGR

Today Liquidia announced it will provide an overview of the company’s business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conf. on Weds., 4/9/25 beginning at 8:45 a.m. ET. Access to a webcast of the presentation will be available at bit.ly/3DSsWXQ.

Yesterday at the Needham Virtual Healthcare Conf., our CEO Roger Jeffs and CFO/COO Michael Kaseta joined Needham Senior Analyst Serge Belanger for a talk about the current state of Liquidia & our plans for the future. An archived webcast is available at bit.ly/3DSsWXQ.

In this phaware® podcast episode, Dr. Raj Parikh discusses the development of the PH-ILD Detection tool. Early detection is critical as there is often a significant delay in diagnosis of PH in ILD patients. #PHILD Hartford HealthCare Team PHenomenal Hope - bit.ly/44o2fVB

In this podcast episode, Dr. Ioana Preston explores the emerging field of #PH associated with interstitial lung disease (PH-ILD), highlighting the importance of early screening & diagnosis #PHILD #phawareMD phaware® Lahey Hospital - bit.ly/4jyiOCG

Liquidia Corporation (NASDAQ: LQDA) announced today it will report its first quarter 2025 financial results on May 8, 2025, via a webcast at 8:30 a.m. ET. For more information, visit bit.ly/4k4dp6N.

Today Judge Kelly of the U.S. District Court for D.C. dismissed, w/out prejudice, the cross-claim filed by United Therapeutics that sought to challenge Liquidia’s amendment to its NDA for YUTREPIA™ (treprostinil) inhalation powder. Read today's press here:

On World PH Day, we’re proud to be raising funds to fuel #pulmonaryhypertension research & support critical services provided to patients in need. Here are several outstanding patient advocacy organizations that could benefit from your support - bit.ly/3Z32j9P.

#LQDA CFO/COO, Michael Kaseta, & CMO, Rajeev Saggar M.D., will provide a business update during a fireside chat at the BofA Securities 2025 Health Care Conf. on Tues, 5/13 at 1:40 pm PT/4:40 pm ET in Las Vegas. Access to the webcast available here: bit.ly/3DSsWXQ.

Liquidia Corporation (NASDAQ: LQDA) announced today its First Quarter 2025 financial results. To hear an archived version of today's webcast, visit our Events and Presentations page located here: bit.ly/3DSsWXQ

This week’s podcast sponsored by Liquidia in concert w/phaware®, features Liquidia Medical Science Liaison, Seth Hall, MBA, RRT discussing the past, present & future of inhaled therapies. Listen here: bit.ly/3YCMxCv

During #WorldPHDay, we helped raise funds to fuel research and critical patient support services that benefit the #pulmonaryhypertension community. Here’s to making a difference together! #PH #PAH #PAHILD

Congratulations to our CEO, Dr. Roger Jeffs, on being named to Business North Carolina's #PowerList 2025 for the third year in a row! To read Roger's best career advice and more, see page 98 of the magazine here: bit.ly/4mucuys.

Liquidia is proud to announce that the U.S. FDA has approved YUTREPIA™ (treprostinil) inhalation powder for patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). See today’s press release here:

Liquidia and several of its employees support the NCBiotech #NCLifeSciences Triangle Women in STEM “2025 STEM Day @ Duke University" – a fun-filled day of STEM activities for 250+ students and their parents/guardians.

Today we announced our participation in the 2025 Jefferies Global Healthcare Conf. where our CEO Dr. Roger Jeffs, CFO/COO Michael Kaseta & CBO Jason Adair will provide a business update on Weds. 6/4 at 11:05 a.m. ET. To register, visit bit.ly/3DSsWXQ.

In this podcast episode, MarcSimonMD discusses diagnosing pulmonary hypertension & shares insights to help docs refine diagnostic approaches w/the potential of achieving better patient outcomes - bit.ly/4dz9rRj phaware® #PHILD #phawareMD UCSF Cardiology California Thoracic Society

The first commercial shipment of YUTREPIA™ (treprostinil) inhalation powder has been scheduled for delivery, marking the first time YUTREPIA will be available at specialty pharmacies. See today’s press release: bit.ly/45BaNsR. For important safety info, see:

On 5/30/25, the U.S. District Court denied United Therapeutics’ request for a preliminary injunction & temporary restraining order in its complaint filed against Liquidia alleging infringement of U.S. Patent No. 11,357,782 (the ‘782 patent). See paragraph 3 of our press release